NAPSRx

The U.S Food and Drug Administration has greenlighted Novo Nordisk’s new drug application (NDA) for Saxenda®  a once daily once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for adults who are obese (BMI ≥30 kg/m2) or who are...

The U.S. Food and Drug Administration has approved Xtoro (finafloxacin otic suspension) to treat acute otitis externa commonly referred to as swimmer's ear.

Pfizer has acquired the development and commercialization rights to OPKO Health’s Long-Acting Human Growth Hormone (hGH-CTP) to treat growth hormone deficiency in adults and children.

The U.S. Food and Drug Administration has approved Eli Lilly’s Cyramza (ramucirumab) for the treatment of metastatic non-small cell lung cancer (NSCLC) which is the most common type of lung cancer and occurs from cancer cells forming in lung tissue.

A new bill has been presented by U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT)  to develop a new pathway for antibiotic drug approvals called the Promise for Antibiotics and Therapeutics for Health (PATH) Act .This act is anticipated to.

Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) has been approved by the U.S.

In an attempt to accelerate their presence in the antibiotics market, Merck will acquire Cubist Pharmaceuticals for $102 per share in cash- this transaction is expected to amount to $9.5 billion.

Incyte Corporation has received approval for Jakafi® (ruxolitinib), the first and only FDA-approved oral medication for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.

Eli Lilly will obtain an exclusive worldwide license from Zosano Pharma Corporation to commercialize their investigational therapy ZP-PTH intended to treat osteoporosis patients.

AstraZeneca and Eli Lilly and Company have recruited their first patient for the AMARANTH Phase II/III study to assess an oral beta secretase cleaving enzyme (BACE) inhibitor called AZD3293 which is currently being developed as a treatment option for...